JPMorgan analyst Anupam Rama raised the firm’s price target on Neurocrine (NBIX) to $145 from $140 and keeps a Neutral rating on the shares. The firm views the company’s Q2 results as solid but maintains a Neutral rating on valuation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine’s Strong Financial Performance and Growth Prospects Drive Buy Rating
- Neurocrine’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Commercial Execution and Growth Opportunities
- Positive Outlook for Neurocrine: Strong Performance and Growth Potential Drive Buy Rating
- Neurocrine Biosciences Reports Strong Q2 2025 Growth
- Neurocrine’s Strong Growth Potential and Positive Outlook Justify Buy Rating